查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012790

抗凝血酶市場：按類型、原料、劑型、劑量形式、治療應用和最終用戶分類－2026-2032年全球市場預測

Antithrombin Market by Type, Source, Form, Dosage Form, Therapeutic Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，抗凝血酶市場價值將達到 7.8032 億美元，到 2026 年將成長至 8.1865 億美元，到 2032 年將達到 10.9515 億美元，年複合成長率為 4.96%。

主要市場統計數據
基準年 2025 780,320,000 美元
預計年份：2026年 8.1865億美元
預測年份 2032 1,095,150,000 美元
複合年成長率 (%) 4.96%

全面介紹了抗凝血酶的生物學、臨床意義、診斷複雜性和治療意義，它塑造了現代凝血醫學。

抗凝血酶是絲胺酸蛋白酶抑制劑，可調節凝血酶和因子Xa的活性，在止血過程中發揮核心作用，其臨床和研究價值在近幾十年顯著提升。臨床醫生面臨頻譜抗凝血酶缺乏症，從遺傳性終身疾病到與嚴重相關的後天性缺乏症，這些都影響著治療決策和風險管理策略。從轉化科學的角度來看，抗凝血酶作為生物標記和治療候選藥物都發揮著至關重要的作用，而血漿來源和重組來源的差異會影響其安全性、免疫抗原性和生產過程等方面的考量。

科學、監管和臨床趨勢正在改變抗凝血酶療法的開發、診斷方法和醫療保健服務模式。

由於科學進步、監管壓力和臨床實踐的不斷發展，抗凝血酶領域正經歷著變革性的變化。重組技術的創新正在減少對血漿來源原料的依賴，引發了更多關於生產規模化、產品均一性和批間差異的討論。同時，檢測準確性的提高和照護現場診斷技術的進步使得早期準確識別抗凝血酶缺乏症成為可能，從而影響著預防策略和高風險環境下的急性期治療管理。

評估 2025 年美國關稅措施如何重塑抗凝血酶供應鏈的供應鏈、採購重點和國內生產策略。

美國2025年實施的關稅政策為抗凝血酶生態系統增添了新的複雜性，影響整個價值鏈的籌資策略和供應商選擇。進口關稅正在影響製造商在本地化生產、填充和包裝業務夥伴關係以及供應鏈路線選擇方面的決策，以降低不斷上漲的接收成本。為此，醫院和大規模綜合醫療網路正在審查供應商契約，並優先考慮多元化和緊急儲備，以維持臨床服務的連續性。

將產品異構體、採購途徑、配方選擇、治療應用和最終用戶需求與臨床引入和開發重點聯繫起來的詳細細分見解。

基於細分市場的分析揭示了不同產品類型和終端使用者因素如何影響抗凝血酶的臨床效用、開發選擇和部署動態。按類型分析，α和BETA異構體由於其不同的生化特性和生理功能，會影響診斷解讀和治療靶點，進而可能影響檢測方法的選擇和個體化治療。依來源分析，人類血漿來源抗凝血酶與重組抗凝血酶的比較凸顯了供體依賴性、病原體安全性以及生產控制方面的權衡取捨，這些因素常常與醫療採購政策和臨床醫生的偏好交織在一起。

從全面的區域觀點解釋美洲、歐洲、中東和非洲以及亞太地區的趨勢如何影響抗凝血酶的生產、監管和臨床應用。

區域趨勢對抗凝血酶的生產、監管和應用有顯著影響，因此，了解地理差異對於策略規劃至關重要。在美洲，臨床網路和醫院系統優先考慮快速獲得急性護理，並維持複雜的採購流程以平衡價格和供應連續性，而區域法規結構強調供體安全和生物製藥可追溯性。在歐洲、中東和非洲地區，監管差異和醫療基礎設施的多樣性導致了廣泛的取得和應用模式。有些市場傾向於集中採購，而有些市場則依賴區域夥伴關係進行供應和低溫運輸物流管理。

本報告從公司層面深入分析了製造商、生物技術創新者和專家合作夥伴如何透過製造、監管策略和臨床合作實現差異化。

抗凝血酶領域的競爭格局和合作框架涵蓋了成熟的生技藥品企業、新興生物技術公司以及專業的合約研發生產機構（CDMO），每家企業都擁有獨特的優勢。有些公司專注於血漿衍生產品的專業知識和供體安全體系，而有些公司則大力投資於重組表達平台和製程改進技術，以提高產量並降低變異性。臨床研究團隊與生產者之間的策略合作日益普遍，有助於快速獲得新適應症的證據，並改善上市後監測。

為高階主管提供切實可行的建議，以加強整個抗凝血酶價值鏈的生產韌性、監管合作和臨床導入策略。

行業領導者應採取一系列切實有效的措施，以應對科學進步、政策轉變和不斷變化的臨床需求。首先，他們應投資於靈活的生產策略，將重組生產能力與地理分散的填充和包裝能力結合，以減少對單一供應商的依賴，並滿足區域採購需求。其次，他們應優先考慮對可靠的分析方法和檢測手段進行外部檢驗，以提高診斷可靠性，並支持其在不同醫療環境中的臨床應用。第三，他們應積極與監管機構合作，就可追溯性、病原體安全措施以及上市後證據的建立達成共識，從而促進產品接受度和長期安全性監測。

該文件清楚地解釋了一種混合方法研究途徑，該方法整合了文獻分析、監管審查、技術評估和專家訪談，有助於實際決策。

本分析整合了來自同行評審文獻、監管文件、臨床試驗註冊資訊、產品標籤、生產白皮書以及與臨床醫生、供應鏈專家和行業專業人士的結構化訪談的證據。關鍵的定性資訊與實驗室審查和配方材料進行了交叉核對，以確保對產品特性和臨床工作流程的全面了解。透過對調查方法研究應用標準化評估標準、交叉參考主要司法管轄區的監管指南以及記錄每項關鍵聲明的資料來源，確保了方法論的嚴謹性。

結論：整合突顯了科學創新、營運韌性和策略參與之間的相互作用，這對於推進抗凝血酵素科學和促進臨床應用至關重要。

總之，抗凝血酶是一個涉及多方面的臨床和技術領域，科學細節、生產選擇和醫療服務現實相互交織。重組技術、診斷準確性和區域生產投資的持續進步正在改變產品的開發、監管和消費方式。貿易政策趨勢凸顯了供應鏈韌性和本地生產能力的重要性，而按異構體、原料、劑型、給藥途徑、治療用途和最終用戶背景進行的細分則強調了製定精心客製化的產品和商業化策略的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：抗凝血酶市場：按類型分類

  • 阿爾法
  • 測試版

第9章：抗凝血酶市場：依來源分類

  • 人類血漿
  • 重組

第10章：抗凝血酶市場：依劑型分類

  • 液體
  • 粉末

第11章 以劑型分類的抗凝血酶市場

  • 注射藥物
  • 口服懸浮液

第12章：依治療應用分類的抗凝血酶市場

  • 後天性缺陷
  • 急性胰臟炎
  • 先天性缺陷
  • 瀰漫性血管內凝血
  • 肝病
  • 敗血症相關凝血障礙

第13章：抗凝血酶市場：依最終用戶分類

  • 門診手術中心
  • 診所
  • 診斷檢查室
  • 醫院
  • 研究機構

第14章：抗凝血酶市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：抗凝血酶市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 抗凝血酶市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國抗凝血酶市場

第18章：中國抗凝血酶市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Baxter International Inc.
  • Bio-Techne Corporation
  • Biocon Ltd.
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • China Biologic Products, Inc.
  • Diapharma Group, Inc.
  • European Medicines Agency
  • F. Hoffmann-La Roche Ltd
  • Genesis BioPharma Services
  • Grifols, SA
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Lee Biosolutions, Inc.
  • LFB USA, Inc.
  • Merck KGaA
  • Novartis AG
  • Octapharma AG
  • Pfizer Inc.
Product Code: MRR-4358BACA8223

The Antithrombin Market was valued at USD 780.32 million in 2025 and is projected to grow to USD 818.65 million in 2026, with a CAGR of 4.96%, reaching USD 1,095.15 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 780.32 million
Estimated Year [2026] USD 818.65 million
Forecast Year [2032] USD 1,095.15 million
CAGR (%) 4.96%

Comprehensive introduction to antithrombin biology, clinical relevance, diagnostic complexity, and therapeutic implications shaping contemporary coagulation care

Antithrombin occupies a central role in hemostasis as a serine protease inhibitor that modulates thrombin and factor Xa activity, and its clinical and research significance has expanded markedly over recent decades. Clinicians encounter antithrombin deficiency across a spectrum that ranges from inherited, lifelong disorders to acquired deficiencies in critical illness, which in turn influence therapeutic decision-making and risk management strategies. From a translational science perspective, antithrombin is consequential both as a biomarker and as a therapeutic agent candidate, with distinctions between plasma-derived and recombinant sources shaping safety, immunogenicity, and manufacturing considerations.

As regulatory frameworks evolve, diagnostic algorithms increasingly integrate antithrombin activity assays with genetic and clinical data to refine case definitions and guide replacement therapy. Furthermore, advances in formulation science and delivery modalities have begun to change how antithrombin products are stored, administered, and integrated into acute and chronic care pathways. Taken together, these elements establish antithrombin as a nexus point between laboratory investigation, bedside practice, and therapeutic innovation, with downstream implications for hospitals, diagnostic laboratories, and research programs seeking to optimize patient outcomes.

Evolving scientific, regulatory, and clinical dynamics that are transforming antithrombin product development, diagnostic approaches, and care delivery models

The landscape surrounding antithrombin is undergoing transformative shifts driven by scientific progress, regulatory pressure, and evolving clinical practice. Innovations in recombinant technology have reduced reliance on plasma-derived sources and have catalyzed discussions about manufacturing scalability, product consistency, and batch-to-batch variability. Concurrently, improvements in assay precision and point-of-care diagnostics are enabling earlier and more accurate identification of antithrombin insufficiency, which affects both prophylactic strategies and acute management in high-risk settings.

In parallel, therapeutic paradigms are being reshaped by a clearer understanding of antithrombin's role in inflammation and endothelial biology, prompting investigation into broader indications beyond classical coagulation disorders. Regulatory scrutiny related to plasma sourcing and pathogen inactivation methods has raised expectations for traceability and safety, while health systems emphasize supply chain resilience and cold chain optimization. As a result, stakeholders across production, clinical, and institutional domains are recalibrating priorities to balance efficacy, safety, and operational feasibility, and these shifts will influence procurement, clinical guidelines, and R&D roadmaps going forward.

Assessment of how the 2025 United States tariff measures recalibrated supply chains, procurement priorities, and domestic production strategies in the antithrombin supply network

United States tariff policies implemented in 2025 have introduced a new layer of complexity for the antithrombin ecosystem, affecting procurement strategies and supplier selection across the value chain. The import tariffs have influenced manufacturer decisions regarding localization of production, partnerships for fill-and-finish operations, and supply chain routing to mitigate incremental landed costs. Hospitals and large integrated delivery networks have responded by revisiting supplier contracts, emphasizing multi-sourcing arrangements and contingency inventories to preserve clinical continuity.

In downstream terms, the tariffs have accelerated conversations about domestic capacity and the feasibility of scaling recombinant production within national borders. Simultaneously, diagnostic laboratories and research institutes have weighed the operational trade-offs associated with alternative sourcing, including increased lead times and the potential need for cold chain redundancies. Although procurement teams navigated near-term administrative burdens, the policy environment also catalyzed strategic investments in local manufacturing partnerships and process optimization initiatives aimed at reducing exposure to future external policy shifts. Looking ahead, stakeholders are increasingly prioritizing resilience, transparency, and adaptive supply frameworks to manage the ripple effects of trade policy on antithrombin accessibility and reliability.

Detailed segmentation insights linking product isoforms, sourcing routes, formulation choices, therapeutic uses, and end-user needs to clinical adoption and development priorities

Segmentation-driven analysis reveals how different product and end-user vectors shape clinical utility, development choices, and adoption dynamics for antithrombin. When examined by type, the distinctions between alpha and beta isoforms inform diagnostic interpretation and therapeutic targeting because biochemical properties and physiological roles vary, which can influence assay selection and treatment tailoring. By source, contrasts between human plasma-derived and recombinant antithrombin highlight trade-offs in donor-dependence, pathogen safety, and manufacturing control, and these factors frequently intersect with institutional procurement policies and clinician preferences.

Considering form factors, the distinctions between liquid and powder formulations matter for storage, shelf life, and reconstitution workflows in clinical settings, and these attributes determine how products are integrated into infusion suites and emergency protocols. Dosage form differentiation between injectable preparations and oral suspensions shapes administration pathways and patient adherence considerations, particularly in ambulatory care and home infusion contexts. Across therapeutic applications, antithrombin is applied in acquired deficiency, acute pancreatitis, congenital deficiency, disseminated intravascular coagulation, liver disease, and sepsis associated coagulopathy, each presenting unique clinical endpoints, monitoring demands, and evidence hierarchies. Finally, end-user segmentation encompassing ambulatory surgical centers, clinics, diagnostic laboratories, hospitals, and research institutes underscores that adoption drivers differ by care setting, with hospitals emphasizing acute use and intensive monitoring, diagnostic laboratories prioritizing assay reliability, and research institutes concentrating on mechanistic studies and translational validation.

Comprehensive regional perspective explaining how Americas, Europe Middle East & Africa, and Asia-Pacific trends influence production, regulation, and clinical access for antithrombin

Regional dynamics exert a powerful influence on how antithrombin is produced, regulated, and deployed, and understanding geographic nuances is essential for strategic planning. In the Americas, clinical networks and hospital systems often prioritize rapid access to acute care therapies and maintain complex procurement protocols that balance price with supply continuity, while regional regulatory frameworks emphasize donor safety and biologic traceability. In Europe, Middle East & Africa, regulatory heterogeneity and variable healthcare infrastructures create a spectrum of access and adoption patterns, with some markets emphasizing centralized procurement and others relying on local partnerships to manage supply and cold chain logistics.

Across the Asia-Pacific region, rising investment in biotechnology manufacturing capacity and growing clinical research activity are reshaping supplier footprints and increasing the availability of recombinant options. Transitional healthcare systems in multiple jurisdictions are also expanding diagnostic capabilities, which improves detection of antithrombin abnormalities and supports evidence generation for diverse therapeutic applications. Taken together, these geographic trends suggest that product strategy, regulatory engagement, and distribution models must be tailored to regional priorities, and that cross-border collaboration and technology transfer will remain important levers for improving availability and clinical outcomes globally.

Key company-level insights describing how manufacturers, biotech innovators, and specialized partners differentiate through manufacturing, regulatory strategy, and clinical collaboration

The competitive and collaborative landscape for antithrombin includes a mix of established biologics manufacturers, emerging biotechnology firms, and specialized contract development and manufacturing organizations, each contributing distinct capabilities. Some players emphasize plasma-derived expertise and donor-safety systems, while others have invested heavily in recombinant expression platforms and process intensification techniques to enhance yield and reduce variability. Strategic alliances between clinical research groups and manufacturers have become more prevalent, enabling accelerated evidence generation for novel indications and improved post-market surveillance frameworks.

In addition, partnerships with specialized logistics providers and diagnostic firms are helping to optimize cold chain integrity and assay standardization, which in turn supports safer and more reliable product deployment. Competitive differentiation increasingly rests on a combination of manufacturing robustness, regulatory lifecycle management, and the ability to supply comprehensive technical support to clinical customers. As stakeholders pursue broader clinical validation and potential label expansions, intellectual property strategies, platform technologies, and manufacturing footprint decisions will continue to shape which companies lead in innovation and where collaborative consortia may offer collective advantages.

Actionable recommendations for executives to enhance manufacturing resilience, regulatory engagement, and clinical adoption strategies across the antithrombin value chain

Industry leaders should adopt a set of pragmatic, high-impact actions to navigate scientific developments, policy shifts, and evolving clinical needs. First, invest in flexible manufacturing strategies that combine recombinant production capabilities with geographically distributed fill-and-finish capacity to reduce single-source exposure and to respond to regional procurement preferences. Second, prioritize robust analytical methods and external validation of assays to improve diagnostic confidence and to support clinical adoption across diverse care settings. Third, engage proactively with regulatory authorities to align on traceability, pathogen-safety approaches, and post-market evidence generation that will facilitate product acceptance and long-term safety monitoring.

Additionally, cultivate strategic partnerships with hospital systems, diagnostic laboratories, and research institutes to co-design real-world evidence generation efforts that demonstrate clinical value across the therapeutic applications where antithrombin may be impactful. Strengthen supply chain resiliency by diversifying logistics partners and investing in cold chain redundancy, while also exploring contract manufacturing relationships that can be scaled quickly in response to policy or demand shifts. Finally, enhance commercial readiness through targeted education for clinicians and procurement teams that clarifies product differentiators, administration workflows, and the implications of source and formulation choices for patient management.

Clear explanation of the mixed-methods research approach integrating literature synthesis, regulatory review, technical assessment, and expert interviews to inform practical decision-making

This analysis synthesizes evidence from peer-reviewed literature, regulatory documents, clinical trial registries, product labelling, manufacturing white papers, and structured interviews with clinicians, supply chain professionals, and industry experts. Primary qualitative inputs were triangulated with laboratory method reviews and formulation dossiers to ensure a comprehensive view of product characteristics and clinical workflows. Methodological rigor was maintained by applying standardized appraisal criteria to clinical studies, cross-referencing regulatory guidance across major jurisdictions, and documenting data provenance for each major assertion.

Where possible, technical assessments of recombinant versus plasma-derived production were corroborated with process descriptions and expert commentary on scalability and quality control. Supply chain and policy impacts were evaluated through scenario analysis and stakeholder interviews to capture operational realities and adaptive strategies. Throughout, the approach emphasized transparency, reproducibility, and practical relevance for decision-makers, and caveats were noted where evidence was evolving or where clinical consensus had not yet been established. This mixed-methods framework ensures that conclusions rest on multiple, corroborative lines of evidence and that recommendations are tailored to real-world operational constraints.

Concluding synthesis emphasizing the interplay of scientific innovation, operational resilience, and strategic engagement necessary to advance antithrombin science and clinical access

In conclusion, antithrombin represents a multifaceted clinical and technological domain where scientific nuance, production choices, and healthcare delivery realities intersect. Ongoing advances in recombinant technologies, diagnostic precision, and regional manufacturing investments are changing how products are developed, regulated, and consumed. Trade policy developments have underscored the importance of supply chain resilience and local capacity, while segmentation across isoform, source, form, dosage form, therapeutic application, and end-user context highlights the need for finely calibrated product and commercialization strategies.

To succeed in this environment, stakeholders must balance innovation with operational reliability, engage early with regulators and clinical opinion leaders, and align manufacturing footprints with regional access imperatives. By combining rigorous evidence generation, strategic partnerships, and adaptive logistics planning, organizations can position themselves to meet clinical demand effectively while also advancing the science of antithrombin therapeutics and diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antithrombin Market, by Type

  • 8.1. Alpha
  • 8.2. Beta

9. Antithrombin Market, by Source

  • 9.1. Human Plasma
  • 9.2. Recombinant

10. Antithrombin Market, by Form

  • 10.1. Liquid
  • 10.2. Powder

11. Antithrombin Market, by Dosage Form

  • 11.1. Injectable
  • 11.2. Oral Suspensions

12. Antithrombin Market, by Therapeutic Application

  • 12.1. Acquired Deficiency
  • 12.2. Acute Pancreatitis
  • 12.3. Congenital Deficiency
  • 12.4. Disseminated Intravascular Coagulation
  • 12.5. Liver Disease
  • 12.6. Sepsis Associated Coagulopathy

13. Antithrombin Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Clinics
  • 13.3. Diagnostic Laboratories
  • 13.4. Hospitals
  • 13.5. Research Institutes

14. Antithrombin Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Antithrombin Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Antithrombin Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Antithrombin Market

18. China Antithrombin Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Baxter International Inc.
  • 19.6. Bio-Techne Corporation
  • 19.7. Biocon Ltd.
  • 19.8. Boehringer Ingelheim Pharma GmbH & Co. KG
  • 19.9. China Biologic Products, Inc.
  • 19.10. Diapharma Group, Inc.
  • 19.11. European Medicines Agency
  • 19.12. F. Hoffmann-La Roche Ltd
  • 19.13. Genesis BioPharma Services
  • 19.14. Grifols, S.A.
  • 19.15. Jiangsu Hengrui Medicine Co., Ltd.
  • 19.16. Lee Biosolutions, Inc.
  • 19.17. LFB USA, Inc.
  • 19.18. Merck KGaA
  • 19.19. Novartis AG
  • 19.20. Octapharma AG
  • 19.21. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTITHROMBIN MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTITHROMBIN MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTITHROMBIN MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTITHROMBIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTITHROMBIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTITHROMBIN MARKET SIZE, BY ALPHA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTITHROMBIN MARKET SIZE, BY ALPHA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTITHROMBIN MARKET SIZE, BY ALPHA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTITHROMBIN MARKET SIZE, BY BETA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTITHROMBIN MARKET SIZE, BY BETA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTITHROMBIN MARKET SIZE, BY BETA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTITHROMBIN MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTITHROMBIN MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTITHROMBIN MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTITHROMBIN MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTITHROMBIN MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTITHROMBIN MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTITHROMBIN MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTITHROMBIN MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTITHROMBIN MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACQUIRED DEFICIENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACQUIRED DEFICIENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACQUIRED DEFICIENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACUTE PANCREATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACUTE PANCREATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACUTE PANCREATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTITHROMBIN MARKET SIZE, BY CONGENITAL DEFICIENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTITHROMBIN MARKET SIZE, BY CONGENITAL DEFICIENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTITHROMBIN MARKET SIZE, BY CONGENITAL DEFICIENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTITHROMBIN MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTITHROMBIN MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTITHROMBIN MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIVER DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIVER DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIVER DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTITHROMBIN MARKET SIZE, BY SEPSIS ASSOCIATED COAGULOPATHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTITHROMBIN MARKET SIZE, BY SEPSIS ASSOCIATED COAGULOPATHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTITHROMBIN MARKET SIZE, BY SEPSIS ASSOCIATED COAGULOPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTITHROMBIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTITHROMBIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTITHROMBIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTITHROMBIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTITHROMBIN MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTITHROMBIN MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTITHROMBIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTITHROMBIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTITHROMBIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTITHROMBIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS ANTITHROMBIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ANTITHROMBIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. GCC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GCC ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 133. GCC ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 134. GCC ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 135. GCC ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. GCC ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. G7 ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 154. G7 ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 155. G7 ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 156. G7 ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. G7 ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. NATO ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 161. NATO ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 162. NATO ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 163. NATO ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. NATO ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)